Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: Immune correlates of cardiovascular co-morbidity in HIV infected participants from South India

Fig. 3

CD4 and CD8 T-cell immune activation between treatment naïve and ART-treated participants stratified by nadir CD4 T-cell counts in comparison to the uninfected control group. CD4 and CD8 T cell immune activation were analyzed by Flow cytometry based on the surface expression of HLA-DR and CD38 dual positive CD4 and CD8 T cells. A, DR+38+: CD4 T-cell activation; B, CD8+DR+38+: CD8 T-cell activation; group 1a: Untreated participants   with nadir CD4 T-cell counts < 200 cells/mm3; group 1b: Untreated participants  with nadir CD4 T-cell counts 200–350 cells/mm3; group 1c: Untreated participants with nadir CD4 T-cell counts > 350 cells/mm3; group 2a: On ART participants with nadir CD4 T-cell counts < 200 cells/mm3; group 2b: On ART participants with nadir CD4 T-cell counts 200–350 cells/mm3; group 2c: On ART patients with nadir CD4 T-cell counts > 350 cells/mm3. Lines with asterix (*) show the significant difference (p < 0.05) between indicated groups with *p < 0.05, **p < 0.01, and ***p < 0.001

Back to article page